Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.
about
Unmet medical needs in systemic lupus erythematosusCgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis.Autoimmunity, end organ damage, and the origin of autoantibodies and autoreactive T cells in systemic lupus erythematosus.The pathogenesis, diagnosis and treatment of lupus nephritis.Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United StatesUrinary biomarkers in lupus nephritis.Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus.Kidney transplantation in patients with systemic lupus erythematosus.Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers.Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United StatesRacial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus NephritisInsulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis.Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritisAmerican College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisUrinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis.Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritisAttribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus RegistryIncidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus RegistryUrinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.Urinary monocyte chemotactic protein-1 and transforming growth factor-β in systemic lupus erythematosus.Predictors of incident proteinuria among patients with SLE.Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach.Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden.Assessment of a lupus nephritis cohort over a 30-year period.After 4 Decades of Lupus Nephritis Trials, Is There a "Best" Therapy?
P2860
Q27005906-F168347C-E218-400E-9A4A-4D45B8AB39EDQ30413753-42819149-67D5-4FFC-9394-D2F633D00753Q30418064-DED14514-1FED-4C89-AFBE-057938A558D1Q30596968-5C431B41-655C-45AD-AA84-BADCBA46A756Q33945242-56E6ACF0-4A85-4E18-8CE6-2AB291DDEE8BQ34050022-A574A714-C48D-443D-AD68-DE92AE06F71AQ34187295-DC98C3E2-3C02-403B-9161-227B517791DEQ34397379-BE124BE0-AE38-4293-B6B3-9379DB27AB90Q35019423-86504843-1F0B-4042-AC59-525415E5E165Q35544692-C9D78C19-236E-430E-9871-8C58355A2A05Q35545690-A9AAABF7-A107-4928-8D86-760EB9AB3F90Q35583267-7BAA6EBD-6046-44E5-B017-9A4293C600A2Q35890096-3A96161A-FBC8-4FA7-8092-96C516E44D1FQ35971689-F0E9BA8E-BA7E-418A-A67F-DC05795F5C14Q36010662-77A97DBC-B10F-400C-B33C-980240B1906DQ36083938-61CA0923-BC6B-4851-AA78-D3AC8A872B4DQ36221407-EB19164B-7EB4-4859-8377-60A3E98561ABQ36259382-3D40AD16-5A7C-4433-BDC6-0A28BD68EBF2Q36354235-FF1A8042-9BB5-4F55-92B7-3C2A79768933Q36517240-2D94787B-016C-4353-BE90-4B80D19FFCA7Q36540787-6C09DCDA-D94D-478F-83D0-095C4A153078Q36713542-59A5A2F1-725A-40EA-B717-6CD9A57D759CQ37352584-6555BE49-4EBE-4882-ABB1-E6A16A584EB5Q37358946-167F93EE-A3A3-46A4-9570-D4F02BA37CECQ37710586-95D217B7-C9C3-4C6D-9001-BBF1A8F26913Q40563547-C94BEF46-DCEC-4839-81EB-092B38E12408Q47100353-1ED66295-ADDC-4B33-B6FC-50937626191CQ47111503-F2565E65-3701-455B-916B-B69BD264BB98Q47385774-EDA7C115-A7BB-4EFE-8975-57E3306E5A13Q50598390-FD3DBAE1-579C-4205-876A-AA702971BBF5Q51048045-4F80F437-2564-45E8-A6F8-93D724566F95Q53096167-22D7C3B0-D8E8-40A5-9F6B-18234519CFE6
P2860
Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Changes in the incidence of en ...... the United States, 1996-2004.
@en
Changes in the incidence of en ...... the United States, 1996-2004.
@nl
type
label
Changes in the incidence of en ...... the United States, 1996-2004.
@en
Changes in the incidence of en ...... the United States, 1996-2004.
@nl
prefLabel
Changes in the incidence of en ...... the United States, 1996-2004.
@en
Changes in the incidence of en ...... the United States, 1996-2004.
@nl
P2860
P356
P1476
Changes in the incidence of en ...... the United States, 1996-2004.
@en
P2093
Michael M Ward
P2860
P356
10.3899/JRHEUM.080625
P407
P577
2009-01-01T00:00:00Z